Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Teacher Retirement System of Texas

Teacher Retirement System of Texas boosted its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 31.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 190,666 shares of the medical research company's stock after acquiring an additional 45,450 shares during the quarter. Teacher Retirement System of Texas' holdings in Amgen were worth $49,695,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of AMGN. Centricity Wealth Management LLC acquired a new stake in shares of Amgen in the fourth quarter valued at about $25,000. Legacy Investment Solutions LLC acquired a new stake in shares of Amgen during the 3rd quarter valued at approximately $29,000. Synergy Investment Management LLC acquired a new stake in shares of Amgen during the 4th quarter valued at approximately $34,000. Atala Financial Inc purchased a new stake in shares of Amgen during the 4th quarter worth approximately $34,000. Finally, Heck Capital Advisors LLC acquired a new stake in shares of Amgen in the 4th quarter worth approximately $36,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,589 shares of the business's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the sale, the senior vice president now directly owns 7,210 shares of the company's stock, valued at $2,195,228.70. The trade was a 18.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP David M. Reese sold 25,225 shares of the business's stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $304.44, for a total value of $7,679,499.00. Following the completion of the sale, the executive vice president now owns 36,922 shares of the company's stock, valued at $11,240,533.68. This trade represents a 40.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 69,341 shares of company stock worth $20,644,335. 0.69% of the stock is currently owned by corporate insiders.

Remove Ads

Amgen Stock Down 2.4 %

Amgen stock traded down $7.52 during midday trading on Tuesday, hitting $306.86. 2,564,825 shares of the company were exchanged, compared to its average volume of 2,551,876. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The company's fifty day moving average price is $298.13 and its 200-day moving average price is $298.50. The company has a market cap of $164.85 billion, a PE ratio of 40.64, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, research analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be given a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.10%. The ex-dividend date of this dividend is Friday, May 16th. Amgen's payout ratio is 126.09%.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Redburn Partners reduced their price objective on Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Johnson Rice set a $294.00 price target on Amgen in a research note on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. UBS Group restated a "hold" rating on shares of Amgen in a research report on Wednesday, February 12th. Finally, Leerink Partners reduced their price target on shares of Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $314.04.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.